智通财经APP讯，友宝在线(02429)发布公告，于2025年9月19日，本公司与配售代理订立配售协议，本 公司同意委任配售代理，而配售代理同意作为本公司的代理尽最大努力促使不少于6名承配人(将为机构 专业投资者，且彼等及彼等的最终实益拥有人将为独立第三方)按配售价每股配售股份2.45港元认购至 多1.575亿股配售股份。 董事们相信，配售事项将有利于增强本集团的流动性和财务状况，扩大本公司股东基础，优化本公司的 资本结构，并支持本公司的健康及可持续发展。 配售事项项下1.575亿股配售股份占截至本公告日期已发行H股数目的约19.96%及已发行股份数目的约 18.94%，及经配发及发行配售股份扩大后的已发行H股数目的约16.64%及已发行股份数目的约15.93% (假设本公司已发行股份数目自本公告日期起至完成配售事项之日为止并无变动)。配售价每股配售股份 2.45港元较H股于2025年9月19日于联交所所报的收市价每股H股2.95港元折让约16.95%。 假设所有配售股份获悉数配售且已完成，预计配售事项的所得款项总额合共约为3.86亿港元，而预计配 售事项的所得款项净额合共约为3.83亿港元。在此基础上，净配 ...

Core Viewpoint - Kingstone Holdings Group (01943) announced a placement agreement with a placement agent to issue up to 150 million shares at a price of HKD 0.617 per share, representing a discount of approximately 19.87% from the closing price of HKD 0.77 on the date of the agreement [1] Group 1 - The placement shares represent approximately 13.04% of the enlarged issued share capital of the company [1] - If all placement shares are fully placed, the total gross proceeds and net proceeds (after deducting placement commission and other expenses) will be approximately HKD 92.55 million and HKD 91.02 million, respectively, equating to a net placement price of about HKD 0.607 per share [1] - The company plans to use approximately HKD 67 million (about 73.61% of the net proceeds) for the development of user-side industrial and commercial energy storage projects and upgrading new industrial parks [1] Group 2 - Approximately HKD 24.02 million (about 26.39% of the net proceeds) will be allocated for general working capital, including repayment of shareholder loans and payment of expenses, salaries and benefits, professional fees, rent, management fees, and other costs [1]

Core Viewpoint - The company, Gilead Sciences, announced a placement and subscription agreement for the sale of 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]

Core Viewpoint - The company, 精优药业, has entered into subscription agreements with three parties to issue new shares at a price of HKD 0.097 per share, which represents a discount to the market price on the date of the agreements [1][2][3] Group 1: Subscription Agreements - The company has signed Subscription Agreement I with subscriber I (曾广钊) to issue 30 million shares, representing approximately 1.26% of the existing issued share capital [1] - Subscription Agreement II was signed with subscriber II (张晓佳) for 20 million shares, equivalent to about 0.84% of the existing issued share capital [1] - Subscription Agreement III was established with subscriber III (Fudan Health International Ltd.) for 110 million shares, accounting for approximately 4.6% of the existing issued share capital [2] Group 2: Financial Implications - If all shares from Subscription Agreement I are successfully issued, the total proceeds will be approximately HKD 2.91 million, with a net amount of about HKD 2.89 million [3] - For Subscription Agreement II, the total proceeds are expected to be around HKD 1.94 million, with a net amount of approximately HKD 1.93 million [3] - The proceeds from Subscription Agreement III are projected to total about HKD 10.67 million, with a net amount of approximately HKD 10.60 million [3] Group 3: Use of Proceeds - The net proceeds from the subscriptions will be utilized for potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [3] - The company aims to expand its health-related business opportunities into overseas markets while continuing to maintain and develop its existing pharmaceutical business through internal cash resources [3]